Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

5 May 2009 07:00

RNS Number : 5915R
ViaLogy PLC
05 May 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

Accuracy of latest oil well predictions independently confirmed

LondonMay 5, 2009Vialogy (LSE:VIY) Following the announcement on 23 April 2009 that a further oil discovery had been made on the Galba Field, Texas ("Mary Ridgeway #1"), ViaLogy is pleased to announce that it has now received detailed analysis confirming the predictions made using its QuantumRD technology on the oil find The successful well was drilled by the leaseholders, Atascosa Exploration LLC of San Antonio.

Using industry standard core analysis practices, Atascosa has received independent confirmation that the well will produce 170,000 barrels of crude oil (i.e. 35% primary recovery based on an overall actual volume of 486,000 barrels).  Atascosa plans extractions of 50% of the recoverable reserves in first three years.  ViaLogy's QuantumRD predictions of hydrocarbon pay zones at depth of 3050 feet with average porosity of 30%, and the oil reservoir's boundaries all proved correct.  With a 10% direct working Interest, ViaLogy expects to receive revenues of approximately $650,000, assuming 35% recovery, over the life of the well (assuming an average per barrel price of $50) to be paid monthly and to begin in Q2 2009.

Atascosa's Senior Geologist, Wilford Stapp commented, "I am very impressed by ViaLogy's ability to combine geological assessment with subsurface seismic interpretation to locate hydrocarbon high saturation zones in consolidated sands.  We have concluded that Mary Ridgeway #1 is a new isolated reservoir in the Bartosh formation with multiple pay zones. ViaLogy's optimized drill location has ensured that this new well will not compete with other producing wells, enhancing our total recovery from the field." Mr. Stapp has Emeritus standing with both the American Association of Petroleum Geologists and Society of Petroleum Engineers; he founded the Publication of the South Texas Geological Society, and was a Fellow of Geological Society of London.  He has been an expert practicing geologist for over 50 years working with majors and independents.  Besides Texas, Mr Stapp has worked in AsiaAustraliaDominican RepublicEnglandFranceMoroccoNamibia, and the Persian Gulf.

ViaLogy has also agreed terms with Atascosa for the drilling of a third well on the Galba Field and discussions are under way for the application of QuantumRD at a number of other Atascosa lease sites.  In addition, Vialogy expects to be working with other customers on additional oil discovery projects in the coming weeks.

Vialogy CEO, Robert Dean, commented, "The accuracy of ViaLogy's QuantumRD analysis and predictions on these first successful wells is impressive.  The technology is widely applicable, and the Company intends to demonstrate its capabilities with an increasing variety of hydrocarbon geological formations and an expanded customer set." 

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656)

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 207 628 5582  

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLUUUCAAUPBGUG
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.